Characterization of Serum and Mucosal SARS-CoV-2-Antibodies in HIV-1-Infected Subjects after BNT162b2 mRNA Vaccination or SARS-CoV-2 Infection.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
21 03 2022
Historique:
received: 25 01 2022
revised: 15 03 2022
accepted: 19 03 2022
entrez: 26 3 2022
pubmed: 27 3 2022
medline: 1 4 2022
Statut: epublish

Résumé

Only limited data are available regarding the immunogenicity of the BNT162b2 mRNA vaccine in HIV-1

Identifiants

pubmed: 35337058
pii: v14030651
doi: 10.3390/v14030651
pmc: PMC8952283
pii:
doi:

Substances chimiques

RNA, Messenger 0
Vaccines, Synthetic 0
Viral Vaccines 0
mRNA Vaccines 0
BNT162 Vaccine N38TVC63NU

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Hector Foundation
ID : M2102
Organisme : German Research Foundation (DFG, graduate school GRK2505)
ID : GRK2504/401821119, project B3

Références

Arthritis Rheumatol. 2021 Dec 23;:
pubmed: 34951137
PLoS One. 2022 Feb 2;17(2):e0263468
pubmed: 35108321
Clin Infect Dis. 2021 Jul 22;:
pubmed: 34293114
J Allergy Clin Immunol. 2021 Feb;147(2):545-557.e9
pubmed: 33221383
J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):527-533
pubmed: 30179984
EClinicalMedicine. 2022 Jan;43:101226
pubmed: 34901799
PLoS One. 2021 Jun 16;16(6):e0249499
pubmed: 34133415
J Infect Dis. 2003 May 15;187(10):1534-43
pubmed: 12721933
EClinicalMedicine. 2021 Jun;36:100928
pubmed: 34109307
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Vaccines (Basel). 2021 Dec 31;10(1):
pubmed: 35062724
J Clin Virol. 2020 Aug;129:104468
pubmed: 32485620
Hum Vaccin Immunother. 2012 Dec 1;8(12):1784-94
pubmed: 22906931
Vaccine. 2009 Jul 23;27(34):4731-8
pubmed: 19540026
NPJ Vaccines. 2022 Feb 28;7(1):28
pubmed: 35228535
Nat Commun. 2021 Oct 5;12(1):5839
pubmed: 34611163
J Med Virol. 2021 Sep;93(9):5257-5259
pubmed: 34009653
J Med Virol. 2022 May;94(5):2230-2236
pubmed: 35106771
Nat Commun. 2021 Jun 28;12(1):3991
pubmed: 34183681
Nat Rev Immunol. 2021 Jun;21(6):395-404
pubmed: 33927374
Lancet Reg Health Eur. 2022 Feb;13:100287
pubmed: 34961855
Clin Microbiol Infect. 2021 Dec;27(12):1851-1855
pubmed: 34438069
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288661
Infection. 2021 Oct 25;:
pubmed: 34694595
Arthritis Rheumatol. 2022 Jan;74(1):33-37
pubmed: 34196506
Pathog Immun. 2021 Jun 7;6(1):116-134
pubmed: 34136730
Lancet HIV. 2021 Jun;8(6):e334-e341
pubmed: 33933189
Int Immunopharmacol. 2022 Jan;102:108383
pubmed: 34824035
J Infect Dis. 2021 Dec 09;:
pubmed: 34888688
Sens Actuators B Chem. 2021 Oct 15;345:130394
pubmed: 34248283
Sci Rep. 2020 Nov 30;10(1):20818
pubmed: 33257702
Med (N Y). 2022 Feb 11;3(2):137-153.e3
pubmed: 35075450
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
AIDS. 2021 Nov 15;35(14):2399-2401
pubmed: 34261097
Science. 2021 Sep 17;373(6561):eabj0299
pubmed: 34529476
EBioMedicine. 2022 Jan;75:103788
pubmed: 34954658
N Engl J Med. 2021 Nov 4;385(19):1774-1785
pubmed: 34551225
Viruses. 2022 Jan 28;14(2):
pubmed: 35215870
Nat Immunol. 2019 Aug;20(8):1059-1070
pubmed: 31308541
Mucosal Immunol. 2008 Jan;1(1):23-30
pubmed: 19079157
Nat Commun. 2020 Jul 24;11(1):3774
pubmed: 32709909
Lancet HIV. 2021 Aug;8(8):e474-e485
pubmed: 34153264
J Infect. 2022 Feb;84(2):248-288
pubmed: 34560135
EClinicalMedicine. 2021 Nov;41:101158
pubmed: 34693234
J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):289-96
pubmed: 18545155
Nat Commun. 2021 Feb 19;12(1):1162
pubmed: 33608522
Viruses. 2021 Feb 04;13(2):
pubmed: 33557418
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Lancet HIV. 2021 Sep;8(9):e568-e580
pubmed: 34416193
Nat Commun. 2021 May 25;12(1):3109
pubmed: 34035301

Auteurs

Katja G Schmidt (KG)

Infectious Diseases and Immunodeficiency Section, Department of Internal Medicine 3, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.

Ellen G Harrer (EG)

Infectious Diseases and Immunodeficiency Section, Department of Internal Medicine 3, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.

Koray Tascilar (K)

Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.

Sabrina Kübel (S)

Institute of Clinical and Molecular Virology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.

Boutaina El Kenz (B)

Infectious Diseases and Immunodeficiency Section, Department of Internal Medicine 3, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Institute of Clinical and Molecular Virology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.

Fabian Hartmann (F)

Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.

David Simon (D)

Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.

Georg Schett (G)

Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.

Krystelle Nganou-Makamdop (K)

Institute of Clinical and Molecular Virology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.

Thomas Harrer (T)

Infectious Diseases and Immunodeficiency Section, Department of Internal Medicine 3, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH